Eli Lilly and Company Ownership
$1,183.46
0.13%
NYSE, Sep 25, 04:16 pm EDT.
Closed.
Index
Industry
Eli Lilly and Company Top Shareholders
| # | Holder | Shares | % of Shares Out | Change | Filing Date |
|---|---|---|---|---|---|
| 1 |
Lilly Endowment, Inc.
|
91.881m | 9.76% | -15.828k | May 06 2026 |
| 2 |
Vanguard Capital Management, LLC
|
53.362m | 5.67% | +53.362m | Mar 31 2026 |
| 3 |
PNC Investments LLC
|
51.123m | 5.43% | -1.167k | Mar 31 2026 |
| 4 |
BlackRock Institutional Trust Company, N.A.
|
41.580m | 4.42% | -263.034k | Mar 31 2026 |
| 5 |
State Street Investment Management (US)
|
35.610m | 3.78% | +248.086k | Mar 31 2026 |
|
1
Lilly Endowment, Inc.
|
9.76%
91.881m
|
|
2
Vanguard Capital Management, LLC
|
5.67%
53.362m
|
|
3
PNC Investments LLC
|
5.43%
51.123m
|
|
4
BlackRock Institutional Trust Company, N.A.
|
4.42%
41.580m
|
|
5
State Street Investment Management (US)
|
3.78%
35.610m
|
| The largest shareholders show who really holds influence: big institutional owners shape a stock's liquidity, and building or cutting positions can move the price. | |
| The 5 largest shareholders together hold 29.06% of Eli Lilly and Company, with Lilly Endowment, Inc. the biggest at 9.76%, followed by Vanguard Capital Management, LLC (5.67%) and PNC Investments LLC (5.43%). |
Recent Eli Lilly and Company Insider Transactions
Powered by
| Date | Insider & Role | Type | Price | Quantity | Volume |
|---|---|---|---|---|---|
| Sep 27 2026 |
John Mitchell
CEO
|
Purchases
|
$182.45 | + 15,000 | $2,736,750 |
| Sep 24 2026 |
Sarah Chen
CFO
|
Sales
|
$179.80 | - 8,500 | $1,528,300 |
| Sep 20 2026 |
Robert Williams
COO
|
Purchases
|
$175.20 | + 12,000 | $2,102,400 |
| Sep 15 2026 |
Emily Rodriguez
Director
|
Sales
|
$181.30 | - 5,200 | $942,760 |
| Sep 09 2026 |
Michael Thompson
SVP Operations
|
Purchases
|
$170.50 | + 20,000 | $3,410,000 |
| Sep 02 2026 |
Lisa Park
General Counsel
|
Sales
|
$177.90 | - 6,800 | $1,209,720 |
| No transactions found for this filter. | |||||
|
John Mitchell
PURCHASES
|
Sep 27 2026
$182.45
|
|
Sarah Chen
SALES
|
Sep 24 2026
$179.80
|
|
Robert Williams
PURCHASES
|
Sep 20 2026
$175.20
|
|
Emily Rodriguez
SALES
|
Sep 15 2026
$181.30
|
|
Michael Thompson
PURCHASES
|
Sep 09 2026
$170.50
|
|
Lisa Park
SALES
|
Sep 02 2026
$177.90
|
| No transactions found for this filter. | |
| Insider transactions show you what executives, directors and major shareholders do with their own stock: people who know the company from the inside. Buys are the most telling signal, because insiders invest their own money. Sells are harder to read, since they can also be driven by taxes, diversification or expiring option programs. |
Eli Lilly and Company Short interest
Powered by
| Short interest shows what share of a stock's freely tradable shares (float) is currently sold short, meaning held by investors betting on falling prices. A high or rising level can be read two ways: it reflects the skepticism of many market participants, but also carries upside potential. Because if the stock rises, short sellers have to buy back, which can push the price up even further. This effect is called a short squeeze. | |
| The short interest in Eli Lilly and Company has held steady at around 0.8% of the float over the past 12 months. Short sellers' positioning has barely changed in this period. |
Register for Free
StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.
